Showing 2401-2410 of 2839 results for "".
- Reveal Lasers Launches Eternahttps://modernaesthetics.com/news/reveal-lasers-launches-eterna-topic/2473419/Reveal Lasers LLC is launching Eterna, a radiofrequency device that reduces fine lines and wrinkles, tightens skin through soft tissue coagulation and does not require consumables. "We are thrilled to introduce Eterna to the market," says Bob Daley, CEO of Reveal Lasers, in a
- Sentient Introduces Tixel in the UShttps://modernaesthetics.com/news/sentient-introduces-tixel-in-the-us/2473416/Sentient is rolling out Sentient Tixel in the US. Sentient Tixel uses thermal-mechanical action technology to resurface skin. Tixel technology uniquely combines heat with the forward motion of a medical-grade titanium tip without the use of lasers, radiation, ultrasound, or needles.
- Evolus Acquires Exclusive US Distribution Rights to Evolysse Line of Dermal Fillershttps://modernaesthetics.com/news/evolus-acquires-exclusive-us-distribution-rights-to-evolysse-line-of-dermal-fillers/2473412/Evolus has entered into a definitive agreement to be the exclusive US distributor of a line of five dermal fillers currently in late-stage development. Evolus is partnering with Symatese, a privately held French company, to introduce the Evolysse line to its US customers beginning
- Plastic Surgeons Among Top Earners in 2022https://modernaesthetics.com/news/plastic-surgeons-among-top-earners-in-2023/2473393/The highest paid specialties in 2022 included plastic surgery ($619,000), orthopedics ($573,000), cardiology ($507,000) and urology ($506,000), according to the 2023 Medscape Physician Compensation Report. Dermatologists made about $443,000 in 2022. T
- New from BTL: Meet EXIONhttps://modernaesthetics.com/news/new-from-btl-meet-exion/2473392/Just in time for their 30th anniversary, BTL is launching EXION, a multiplatform device featuring micro-needling RF, a non-invasive face and body applicator for skin laxity, and the EMFEMME 360 applicator for intimate health. EXION can also be combined with EMFACE to treat bot
- Dermalogica Offers Digital Accreditation Badge for Beauty Proshttps://modernaesthetics.com/news/dermalogica-offers-digital-accreditation-badge-for-beauty-profs/2473391/Dermalogica is launching a new medispa accreditation for professional skin therapists. Launching April 17, 2023, the program aims to raise industry standards and provide more transparency to consumers. Unlike state board requirements that lead to esthetics licensing, the
- New Research Reveals Anti-Aging Potential Found in an Invasive Weedhttps://modernaesthetics.com/news/new-research-reveals-anti-aging-potential-found-in-an-invasive-weed/2473385/The fruit of the cocklebur plant, which grows worldwide and is often considered a noxious weed, has antioxidant and anti-inflammatory components that could make it useful as a skin protectant, according to new research
- Establishment Labs Surpasses 3 Million Motiva Deviceshttps://modernaesthetics.com/news/establishment-labs-surpasses-3-million-motiva-devices/2473383/Establishment Labs Holdings announced that it has surpassed 3 million Motiva devices in market. The devices have been delivered to plastic and reconstructive surgeons since 2010 and are available in more than 85 countries. “Since its founding, Establishment Labs has been guid
- Aziyo Biologics, Sientra Partner to Distribute SimpliDerm Productshttps://modernaesthetics.com/news/aziyo-biologics-sientra-partner-to-distribute-simpliderm-product-line/2473379/Aziyo Biologics, Inc. and Sientra, Inc. are joining forces to expand the distribution of Aziyo’s SimpliDerm product line. Under the agreement terms, Aziyo will grant Sientra certain non-exclusive rights in the United States to market, sell, and distribute SimpliDerm fo
- Sientra Announces First Shipment of Viality Fat Transfer System; New Preliminary Datahttps://modernaesthetics.com/news/sientra-launches-viality-fat-transfer-system/2473374/Sientra announced that it has begun commercial shipping of its Viality with AuraClens fat transfer system. The company also announced the release of preliminary results from its ongoing, multicenter, long-term volume retention clinical study with Viality. These results show over 80% vol